

**Biotechnology Fund**  
**SCHEDULE OF INVESTMENTS (Unaudited)**

December 31, 2018

|   | Shares     | Value                 |
|---|------------|-----------------------|
| <b>COMMON STOCKS<sup>†</sup> - 100.0%</b>                                 |            |                       |
| <b>Biotechnology - 72.3%</b>  |            |                       |
| Amgen, Inc.   | 75,428     | \$ 14,683,569         |
| Gilead Sciences, Inc.   | 181,739    | 11,367,774            |
| Biogen, Inc.*   | 34,487     | 10,377,828            |
| Shire plc ADR   | 54,319     | 9,453,679             |
| Vertex Pharmaceuticals, Inc.*   | 52,205     | 8,650,891             |
| Celgene Corp.*  | 133,787    | 8,574,409             |
| Illumina, Inc.*   | 28,499     | 8,547,705             |
| Regeneron Pharmaceuticals, Inc.*  | 22,477     | 8,395,159             |
| Alexion Pharmaceuticals, Inc.*  | 61,132     | 5,951,812             |
| BioMarin Pharmaceutical, Inc.*  | 60,049     | 5,113,172             |
| Incyte Corp.*   | 75,244     | 4,784,766             |
| Seattle Genetics, Inc.*   | 70,748     | 4,008,582             |
| Anylam Pharmaceuticals, Inc.*   | 50,940     | 3,714,035             |
| Ionis Pharmaceuticals, Inc.*  | 66,758     | 3,608,937             |
| Exact Sciences Corp.*   | 56,720     | 3,579,032             |
| Exelixis, Inc.*   | 165,508    | 3,255,542             |
| Bluebird Bio, Inc.*   | 30,050     | 2,980,960             |
| United Therapeutics Corp.*  | 26,306     | 2,864,723             |
| Sage Therapeutics, Inc.*  | 29,816     | 2,856,075             |
| Loxo Oncology, Inc.*  | 18,908     | 2,648,444             |
| FibroGen, Inc.*   | 56,787     | 2,628,102             |
| Intercept Pharmaceuticals, Inc.*  | 21,829     | 2,200,145             |
| Ligand Pharmaceuticals, Inc. — Class B*                                   | 16,161     | 2,193,048             |
| ACADIA Pharmaceuticals, Inc.*   | 127,939    | 2,068,774             |
| Myriad Genetics, Inc.*  | 66,603     | 1,936,149             |
| Ultragenyx Pharmaceutical, Inc.*  | 44,160     | 1,920,077             |
| Immunomedics, Inc.* <sup>1</sup>  | 132,756    | 1,894,428             |
| PTC Therapeutics, Inc.*   | 50,660     | 1,738,651             |
| Spark Therapeutics, Inc.*   | 39,426     | 1,543,134             |
| REGENXBIO, Inc.*  | 35,780     | 1,500,971             |
| Medicines Co.* <sup>1</sup>   | 78,326     | 1,499,160             |
| Spectrum Pharmaceuticals, Inc.*   | 132,630    | 1,160,512             |
| <b>Total Biotechnology</b>  |            | <b>147,700,245</b>    |
| <b>Pharmaceuticals - 25.1%</b>  |            |                       |
| AbbVie, Inc.  | 169,303    | 15,608,044            |
| Sarepta Therapeutics, Inc.*   | 35,358     | 3,858,618             |
| Neurocrine Biosciences, Inc.*   | 45,049     | 3,216,949             |
| PRA Health Sciences, Inc.*  | 33,096     | 3,043,508             |
| Nektar Therapeutics*  | 90,221     | 2,965,564             |
| Jazz Pharmaceuticals plc*   | 23,305     | 2,888,888             |
| TESARO, Inc.*   | 35,111     | 2,606,992             |
| Alkermes plc*   | 78,250     | 2,309,157             |
| Array BioPharma, Inc.*  | 157,503    | 2,244,418             |
| Global Blood Therapeutics, Inc.*  | 49,933     | 2,049,750             |
| Agios Pharmaceuticals, Inc.*  | 44,168     | 2,036,586             |
| Heron Therapeutics, Inc.*   | 74,140     | 1,923,192             |
| Madrigal Pharmaceuticals, Inc.*   | 16,060     | 1,810,283             |
| Supernus Pharmaceuticals, Inc.*   | 52,146     | 1,732,290             |
| Portola Pharmaceuticals, Inc.*  | 83,210     | 1,624,259             |
| Clovis Oncology, Inc.*  | 71,560     | 1,285,218             |
| <b>Total Pharmaceuticals</b>  |            | <b>51,203,716</b>     |
| <b>Healthcare-Products - 1.4%</b>   |            |                       |
| Bio-Techne Corp.  | 20,558     | 2,975,154             |
| <b>Healthcare-Services - 1.2%</b>   |            |                       |
| Syneos Health, Inc.*  | 63,310     | 2,491,248             |
| <b>Total Common Stocks</b><br>(Cost \$112,206,522)                        |            | <b>204,370,363</b>    |
| <b>RIGHTS<sup>†††</sup> - 0.0%</b>  |            |                       |
| Clinical Data, Inc.* <sup>2</sup>   | 24,000     | -                     |
| <b>Total Rights</b><br>(Cost \$-)   |            | <b>-</b>              |
| <b>Face Amount</b>  |            |                       |
| <b>REPURCHASE AGREEMENTS<sup>††3</sup> - 0.6%</b>                         |            |                       |
| JPMorgan Chase & Co.<br>issued 12/31/18 at 2.95%<br>due 01/02/19          | \$ 720,374 | 720,374               |
| Barclays Capital<br>issued 12/31/18 at 2.93%<br>due 01/02/19              | 299,583    | 299,583               |
| Bank of America Merrill Lynch<br>issued 12/31/18 at 2.95%<br>due 01/02/19 | 199,722    | 199,722               |
| <b>Total Repurchase Agreements</b><br>(Cost \$1,219,679)                  |            | <b>1,219,679</b>      |
| <b>Shares</b>   |            |                       |
| <b>SECURITIES LENDING COLLATERAL<sup>†,4</sup> - 0.6%</b>                 |            |                       |
| <b>Money Market Fund</b>  |            |                       |
| First American Government Obligations Fund — Class Z, 2.32% <sup>5</sup>  | 1,191,993  | 1,191,993             |
| <b>Total Securities Lending Collateral</b><br>(Cost \$1,191,993)          |            | <b>1,191,993</b>      |
| <b>Total Investments - 101.2%</b><br>(Cost \$114,618,194)                 |            |                       |
| <b>Other Assets &amp; Liabilities, net - (1.2)%</b>                       |            | <b>(2,499,047)</b>    |
| <b>Total Net Assets - 100.0%</b>  |            | <b>\$ 204,282,988</b> |

\* Non-income producing security.

<sup>†</sup> Value determined based on Level 1 inputs.

<sup>††</sup> Value determined based on Level 2 inputs.

<sup>†††</sup> Value determined based on Level 3 inputs.

<sup>1</sup> All or a portion of this security is on loan at December 31, 2018.

<sup>2</sup> Security was fair valued by the Valuation Committee at December 31, 2018. The total market value of fair valued securities amounts to \$0, (cost \$0) or 0.0% of total net assets.

<sup>3</sup> Repurchase Agreements.

<sup>4</sup> Securities lending collateral.

<sup>5</sup> Rate indicated is the 7-day yield as of December 31, 2018.

---

*ADR* — American Depositary Receipt  
*plc* — Public Limited Company